ImmunityBio's Stock Surge Driven by Anktiva Revenue Growth

ImmunityBio (NASDAQ:IBRX), a developer of cancer and infectious disease therapies, experienced a significant stock surge, closing at $3.95, which marks a 30.79% increase in a single trading session. This rise followed the release of preliminary 2025 results indicating a remarkable 700% growth in revenue from its bladder cancer therapy, Anktiva. The company's quarterly sales exceeded Wall Street expectations, with projections estimating Anktiva's revenue to jump from $15 million in 2024 to $113 million in 2025, reflecting a 20% increase quarter over quarter.

Nasdaq

The broader market also saw positive movement, with the S&P 500 rising by 0.27% to close at 6,945 and the Nasdaq Composite gaining 0.25% to finish at 23,530. In the biotechnology sector, ImmunityBio outperformed its peers, such as Incyte, which closed at $105.24 (-0.67%), and Vertex Pharmaceuticals, ending at $438.92 (-2.36%).

Nasdaq

The surge in ImmunityBio's stock can be attributed to several key developments. Notably, the Saudi Food and Drug Authority recently approved Anktiva, which contributed to the spike in share prices. Additionally, positive data regarding Anktiva's efficacy in treating non-small cell lung cancer was released just days prior, suggesting potential for further market expansion.

Nasdaq

Investors are closely monitoring ongoing demand trends for Anktiva and potential label expansions that could enhance the therapy's market presence. The trading volume for ImmunityBio reached 70.4 million shares, significantly surpassing its three-month average of 13 million shares, indicating heightened investor interest.

Nasdaq

Despite the positive outlook, some analysts caution that ImmunityBio remains a volatile investment. The company has seen a substantial decline of 89% since its initial public offering in 2015, raising concerns about its long-term sustainability and market performance.

Nasdaq

Management at ImmunityBio expressed optimism regarding the company's growth trajectory, particularly in light of the recent approvals and positive clinical data. They emphasized the potential for Anktiva to expand into new geographic markets and indications, positioning the company as a noteworthy player in the healthcare sector.

Nasdaq

• “What this means for investors ImmunityBio's fantastic week continued on Thursday, after management released preliminary full-year earnings that exceeded Wall Street's expectations.” — Analyst Commentary

Nasdaq

• “These positive results come one day after the Saudi Food and Drug Authority approved Anktiva in the country, which also prompted a share price spike.” — Market Analysis

Nasdaq

As ImmunityBio navigates this pivotal moment, its future performance will depend on the sustained demand for Anktiva and the successful execution of its growth strategies.

Nasdaq